ClinicalTrials.gg
RecruitingNCT06696534MS-CareUpdated Oct 2, 2025

Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme

An interventional study of Survey using a questionnaire. and Survey using a questionnaire. in Screening for Colon Cancer and Survey and Questionnaire, sponsored by ADVANCED MARKER DISCOVERY S.L.. Recruiting at 2 sites in 2 countries. Open to participants aged 50 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by ADVANCED MARKER DISCOVERY S.L. · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
50 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies in Colorectal Neoplasms with a site in Portugal — 8 open to participants now, 15 under way, 6 of them phase 3. Colorectal Neoplasms · Portugal.

Planned enrollment
10th of 41
1,000 · median 680
Started
2025
with 2 others
No phase
5 of 53
2 open now
Primary completion
2025-11
later than 2 of 14 live
Registered
48th of 53
by date
Lead sponsor
2 of 53
ADVANCED MARKER DISCOVERY S.L.

Among the 53 studies in Colorectal Neoplasms with a site in Portugal, this one is the 10th largest by planned enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, reaches primary completion later than 2 of the 14 other live ones, and was the 48th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

8 of the 53 studies in Colorectal Neoplasms with a site in Portugal are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 50 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Colorectal Neoplasms with a site in Portugal, or all of them as a file.
02

Study summary

The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant population for colorectal cancer; could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to answer are:

  • Values of experience of participants into screening programme.
  • Values of preferences of participants for screening methods.

Participants will answer two questionnaires and they'll be given their information and clinical data to investigator or health personnel.

03

Conditions studied

  • Screening for Colon Cancer
  • Survey and Questionnaire

Keywords

  • colorectal cancer
  • screening programme
  • experience
  • preference
  • questionnaire
04

Who can participate

Ages eligible
50 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants ages from 50 to 69 years (both included) at the time of signed.
  • Participants invited to participate in population-based screening programme who are eligible to undertake FOBT at the Primary Health Care Center.
  • Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Participants who have not delivery a stool sample in the Primary Health Care Center before signing the form.
  • Participants with a previous colonoscopy in consequence of a FOBT positive result.
  • Participants who are in a dependent personal or non-medical relationship with the Sponsor or the Investigators.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Other
    FIT/FOBT population

    Average-risk population undergoing FIT/FOBT within the colorectal cancer screening programme.

    Other: Survey using a questionnaire.

Interventions

  • OtherSurvey using a questionnaire.

    Preference questionnaire for colorectal cancer screening methods

  • OtherSurvey using a questionnaire.

    Experience questionnaire into colorectal cancer screening programme

06

What researchers measure

Primary outcomes

  1. Value of questionnaires into screening programme

    The percentage of number of answers from each experience and preference questions

    Time frame: 12 months

07

Study locations

1 of 2 sites recruiting
  • UCSP Sete Rios
    Lisbon, Portugal
    Not yet recruiting
    • Ana Rita, MD · Contact
  • CS Mar Báltico
    Madrid, Madrid, Spain
    Recruiting
    • Maria A Perez, MD · Contact
08

References and documents

Publications

  • Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, Dhein J, Zimmermann M, Tauber R, Wiedenmann B. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014 Oct 17;14:183. doi: 10.1186/1471-230X-14-183. PubMed 25326034 ↗
  • De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque Lopez MD, Innos K, Santaquilani M, Blum M, Ventura L, Paapsi K, Galasso R, Guevara M, Randi G, Bettio M, Botta L, Guzzinati S, Dal Maso L, Rossi S; EUROCARE-6 Working Group. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol. 2024 Mar;25(3):293-307. doi: 10.1016/S1470-2045(23)00646-0. Epub 2024 Jan 30. PubMed 38307102 ↗
  • Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1. PubMed 36856579 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2025, 6 months after the start.

Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's planned 6 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 20, 2024
StartActual
May 19, 2025
Primary completionEst.
Nov 2025
CompletionEst.
Dec 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06696534
Lead sponsor
ADVANCED MARKER DISCOVERY S.L.
Collaborators
SERMAS, ULS de Santa Maria
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
May 19, 2025
Primary completion
Nov 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 2, 2025

Study contacts

Marta Jimenez, PhD
Contact
mjimenez@amadix.com
+34 637899149
Maria A Perez, MD
principal investigator · Primary Health Care Centre Mar Báltico
Ana Rita, MD
principal investigator · Unidade Local de Saúde Santa Maria

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion